Artigos Científicos

  • Artigos Científicos Relacionados  à Vacinação e ao Sistema Imunológico

Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations

The economic impact of HPV vaccines: not just cervical cancer

Cervical Cancer and HPV Vaccines in Developing Countries

HPV vaccines

The role of human papillomavirus vaccines in cervical neoplasia

HPV and cervical cancer: screening or vaccination?

Current prophylactic HPV vaccines and gynecologic premalignancies

Harnessing the power of prevention: human papillomavirus vaccines

Efficacy and other milestones for human papillomavirus vaccine introduction

Efficacy of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against cervical intraepithelial neoplasia grades 1–3 and adenocarcinoma in situ A combined analysis

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

Are women ready for the HPV vaccine?

Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists

Cervical cancer vaccination indications, efficacy, and side effects

Prospects for therapeutic HPV vaccines

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

Human papillomavirus vaccination in males

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

Immunobiology of HPV and HPV vaccines

Long-term efficacy of human papillomavirus vaccination

Prevention strategies against the human papillomavirus: The effectiveness of vaccination

Prevention strategies of cervical cancer in the HPV vaccine era

The Future Is Now: Advances With Vaccines for the Prevention of Cervical Cancer and Other HPV-Related Diseases

Prévention du cancer du col utérin: enjeux et perspectives de la vaccination antipapillomavirus

HPV Vaccination – More Answers, More Questions

Human Papillomavirus Vaccine — Opportunity and Challenge

Vaccination to Prevent and Treat Cervical Cancer

A public health approach to cervical cancer control: Considerations of screening and vaccination strategies

Delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community

HPV vaccination and screening to eliminate cervical cancer

HPV vaccines

Vaccination against HPV: indications for women and the impact on the cervical screening programme

Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine

Prevention of recurrent respiratory papillomatosis: Role of HPV vaccination

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine

Public health paradoxes and the epidemiological impact of an HPV vaccine

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

Introducing HPV Vaccine in Developing Countries – Key Challenges and Issues

HPV VaccinesProphylactic, Not Therapeutic

FDA Licensure of Quadrivalent Human Papillomavirus Vaccine for use in Males and Guidance From the Advisory Committee on Immunization Practices

Vaccines against rotavirus and human papillomavirus (HPV)

Vaccination prophylactique et thérapeutique contre le papillomavirus humain

Acceptability of Human Papillomavirus Vaccine for Males: A Review of the Literature

HPV Vaccines: Today and in the Future

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

Vaccination as a prevention strategy for human papillomavirus-related diseases

Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report

Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination

Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

Vaccines

How will HPV vaccines affect cervical cancer?

Uptake of the Human Papillomavirus Vaccine: A Review of the Literature and Report of a Quality Assurance Project

Vaccinating Men for HPV: New Strategy for Preventing Cervical Cancer In Women?

Vaccination anti-HPV

Quadrivalent Human Papillomavirus Vaccine

Cancer Vaccines: Between the idea and the reality

Prevention of Cervical Cancer Through Papilloma Virus Vaccination

Acceptability of the Human Papillomavirus Vaccine among Latina Mothers

HPV vaccine

Cervical response to vaccination against HPV16 E7 in case of severe dysplasia

Effect of Human Papillomavirus Vaccines on Vulvar, Vaginal, and Anal Intraepithelial Lesions and Vulvar Cancer

Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women

Politics, Parents, and Prophylaxis – Mandating HPV – Vaccination in the United States

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Particle Vaccine in Male and Female Adolescents and Young Adult Women

Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

Background to a vaccination programme for the human papilloma virus in Sweden 2007

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

Papillomavirus vaccines in clinical trials

Preliminary HPV vaccine results for women older than 25 years

Preliminary HPV vaccine results for women older than 25 years

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Safety, immunogenicity, and effi cacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind tria

HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Quadrivalent Vaccine against Human Papillomavirus  to Prevent High-Grade Cervical Lesions

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Quadrivalent Vaccine against Human Papillomavirus  to Prevent High-Grade Cervical Lesions

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome

Age for HPV vaccination

Approaches to monitoring biological outcomes for HPV vaccination: Challenges of early adopter countries

Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine

Cervical cancer screening following prophylactic human papillomavirus vaccination

Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms

Chapter 14: HPV vaccine introduction in industrialized countries

Chapter 15: HPV vaccine use in the developing world

Chapter 16: HPV vaccines in immunocompromised women and men

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries

Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

Developing an HPV vaccine to prevent cervical cancer and genital warts

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study

Human Papillomavirus Vaccine Introduction – The First Five Years

UK will use Gardasil in its HPV vaccination programme from next September

Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services

Strongly Decreased Risk of GenitalWarts After Vaccination Against Human Papillomavirus: Nationwide Follow-up of Vaccinated and Unvaccinated Girls in Denmark

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study

Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence

Ethical analysis of HPV vaccine policy options

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

Immunogenicity of an HPV-16 L2 DNA vaccine

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Innate immunity and vaccine

Is viral status needed before vaccination?

Knowledge differences between male and female university students about human papillomavirus (HPV) and cervical cancer: Implications for health strategies and vaccination

Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases

Quadrivalent Human Papillomavirus Vaccine

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors

Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types

HPV vaccines: Commercial Research & Development

Prophylactic HPV vaccines: Underlying mechanisms

Current findings from prophylactic HPV vaccine trials

HPV vaccine introduction in industrialized countries

HPV vaccine use in the developing world

HPV vaccines in immunocompromised women and men

Issues in planning cervical cancer screening in the era of HPV vaccination

Modelling the impact of HPV vaccines on cervical cancer and screening programmes

Assuring the quality, safety and efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure

Psychosocial aspects of vaccine acceptability

Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries

Research needs following initial licensure of virus-like particle HPV vaccines

Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

A human papillomavirus type 16 vaccine by oral delivery of L1 protein

The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development

Vaccines for papillomavirus infection

Current prophylactic HPV vaccines and gynecologic premalignancies

Human papilloma virus vaccine – more than a vaccine

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program

Early eff ect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

Evidence of Human Papillomavirus Vaccine-Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–2010

Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11

HPV infection and HPV-associated neoplasia in immunocompromised women

Correlating immunity with protection for HPV infection

Immunization against human papillomavirus infection and associated neoplasia

Immune responses to human papillomavirus

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection

HPV 18 antibody levels, clinical efficacy and induced immune memory: A trio?

Prophylactic DNA immunization against multiple papillomavirus types

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer

Clinical and epidemiological correlates of antibody response to Human Papillomaviruses (HPVs) as measured by a novel ELISA  based on denatured recombinant HPV16 late (L) and early (E) antigens

Prevenção da Infecção por HPV e Lesões Associadas com o Uso de Vacinas

A eficácia da vacina profilática contra o HPV nas lesões HPV induzidas

  • Artigos Relacionados ao Câncer

Generation of tumor, specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

The role of human papillomavirus in head and neck cancer

A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland

The role of human papillomavirus in head and neck cancer

The role of viral integration in the development of cervical cancer

Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer

Cervical cancer screening: state of the art

The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?

New paradigm for prevention of cervical cancer

Global
 Guidance 
For 
Cervical 
Cancer 
Prevention 
and 
Control

Natural history and epidemiology of HPV infection and cervical cancer

Secondary prevention of cervical cancer

Human papillomavirus infection and the development of cervical cancer and related genital neoplasias

Environmental risk factors for prevention and molecular intervention of cervical cancer

HPV DNA Testing in Cervical Cancer Screening / Results From Women in a High-Risk Province of Costa Rica

Papilloma Viruses and Cancer: From Basic Studies to Clinical Application

Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study

HPV and oral contraceptives linked to cervical cancer risk

Cervical cancer: From Hippocrates through Rigoni-Stern to zur Hausen

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling

New dimensions in cervical cancer screening

Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling

Cost-effectiveness of cervical cancer screening

Human Papillomavirus and Cervical Cancer

The new challenges in the prevention of cervical cancer

HPV in the etiology of human cancer

The burden of HPV-related cancers

Screening for cervical cancer in developing countries

Update of HPV-Associated Female Genital Cancers in the United States, 1999–2004

Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Updating the natural history of HPV and anogenital cancer

EUROGIN 2007 roadmap on cervical cancer prevention

The epidemiology of human papillomavirus infection and its association with cervical cancer

Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses

Human Papillomaviruses in Head and Neck Carcinomas

Rate of Human Papillomavirus Clearance After Treatment of Cervical Intraepithelial Neoplasia

Persistent human papillomavirus infection and cervical neoplasia

Infection and Cervical Neoplasia: Facts and Fiction

Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?

HPV prevalence among partners of women with cervical intraepithelial neoplasia

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

The economic burden of noncervical human papillomavirus disease in the United States

Human Papillomaviruses in Head and Neck Carcinomas

  • Artigos Relacionados ao Papilomavírus Humano (Infecção, Detecção, História, Epidemiologia)

Epidemiology of recurrent respiratory papillomatosis

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection

Epidemiology and transmission dynamics of genital HPV infection

Weekly epidemiological record Relevé épidémiologique hebdomadaire

Human Papilloma Virus DNA Detection In Male Sexual Partners Of Women With Genital Human Papilloma Virus Infection

Human papilloma virus infection prior to coitarche

Current concepts on human papillomavirus infections in children

Methods for HPV detection in exfoliated cell and tissue specimens

The natural history of human papillomavirus infections of the mucosal epithelia

High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum

Effectiveness of condoms in preventing sexually transmitted infections

Human papillomavirus-associated diseases in HIV-infected men who have sex with men

Infecção pelo Papiloma Vírus Humano (HPV) em mulheres de Florianópolis, Santa Catarina

Cervical Human Papillomavirus Screening among Older Women

Human papilloma virus infection prior to coitarche

Biology of genital human papillomaviruses

Clinical manifestations of HPV infection

How to manage and communicate with patients about HPV?

Methods for detection of HPV infection and its clinical utility

Pathology of HPV infection at the cytologic and histologic levels: Basis for a 2-tiered morphologic classification system

Persistent HPV infection in postmenopausal age women

Prevalence of HPV infection by cervical cytologic status in Brazil

Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women

Human papillomavirus cervical infection in Guarani Indians from the rainforest of Misiones, Argentina

The role of HPV type in Recurrent Respiratory Papillomatosis

Prevalence of HPV Infection Among Females in the United States

Human Papillomavirus-Related Disease in Men: Not Just a Women’s Issue

Molecular diagnosis of human papillomavirus (HPV) infections

Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues

The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses

The papillomavirus life cycle

Winter 2002

Human Papillomavirus Infection in Postmenopausal Women With and Without Hormone Therapy

Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae

Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events?

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

Recurrent Respiratory Papillomatosis: A Review

Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD

Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer

Achievements and limitations of cervical cytology screening

Clinical applications of HPV testing: A summary of meta-analyses

International Standard reagents for harmonization of HPV serology and DNA assays—an update

Editorial

Conference Report

Preface

Editorial

Perspectives of contemporary papillomavirus research

Disclosure of financial support

Classification of papillomaviruses

Perinatal transmission of human papilomavirus DNA

Transplacental transmission of Human Papillomavirus

Sexually Transmitted Infections Issue

Jornais e Revistas

Publicações em Jornais e Revistas leigas:
Informativo ABG: Patologia do trato genital inferior
Boletim SOGISC – Sociedade de Ginecologia e Obstetrícia de Santa Catarina
Jornal da Febrasgo
Jornal do Brasil – Vida/Saúde e Ciência

Entrevistas

Em breve sobre os 50 anos do exame de Papanicolau.